263 related articles for article (PubMed ID: 16885371)
1. Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases.
Springfeld C; von Messling V; Frenzke M; Ungerechts G; Buchholz CJ; Cattaneo R
Cancer Res; 2006 Aug; 66(15):7694-700. PubMed ID: 16885371
[TBL] [Abstract][Full Text] [Related]
2. Liver cancer protease activity profiles support therapeutic options with matrix metalloproteinase-activatable oncolytic measles virus.
Mühlebach MD; Schaser T; Zimmermann M; Armeanu S; Hanschmann KM; Cattaneo R; Bitzer M; Lauer UM; Cichutek K; Buchholz CJ
Cancer Res; 2010 Oct; 70(19):7620-9. PubMed ID: 20858718
[TBL] [Abstract][Full Text] [Related]
3. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter.
Hasegawa K; Pham L; O'Connor MK; Federspiel MJ; Russell SJ; Peng KW
Clin Cancer Res; 2006 Mar; 12(6):1868-75. PubMed ID: 16551872
[TBL] [Abstract][Full Text] [Related]
4. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response.
Gauvrit A; Brandler S; Sapede-Peroz C; Boisgerault N; Tangy F; Gregoire M
Cancer Res; 2008 Jun; 68(12):4882-92. PubMed ID: 18559536
[TBL] [Abstract][Full Text] [Related]
5. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme.
Liu C; Sarkaria JN; Petell CA; Paraskevakou G; Zollman PJ; Schroeder M; Carlson B; Decker PA; Wu W; James CD; Russell SJ; Galanis E
Clin Cancer Res; 2007 Dec; 13(23):7155-65. PubMed ID: 18056196
[TBL] [Abstract][Full Text] [Related]
6. Generation of a recombinant Sendai virus that is selectively activated and lyses human tumor cells expressing matrix metalloproteinases.
Kinoh H; Inoue M; Washizawa K; Yamamoto T; Fujikawa S; Tokusumi Y; Iida A; Nagai Y; Hasegawa M
Gene Ther; 2004 Jul; 11(14):1137-45. PubMed ID: 15085175
[TBL] [Abstract][Full Text] [Related]
7. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma.
Blechacz B; Splinter PL; Greiner S; Myers R; Peng KW; Federspiel MJ; Russell SJ; LaRusso NF
Hepatology; 2006 Dec; 44(6):1465-77. PubMed ID: 17133484
[TBL] [Abstract][Full Text] [Related]
8. Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin.
Liu S; Netzel-Arnett S; Birkedal-Hansen H; Leppla SH
Cancer Res; 2000 Nov; 60(21):6061-7. PubMed ID: 11085528
[TBL] [Abstract][Full Text] [Related]
9. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus.
Anderson BD; Nakamura T; Russell SJ; Peng KW
Cancer Res; 2004 Jul; 64(14):4919-26. PubMed ID: 15256464
[TBL] [Abstract][Full Text] [Related]
10. The role of subtilisin-like proprotein convertases for cleavage of the measles virus fusion glycoprotein in different cell types.
Bolt G; Pedersen IR
Virology; 1998 Dec; 252(2):387-98. PubMed ID: 9878618
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies.
Ong HT; Hasegawa K; Dietz AB; Russell SJ; Peng KW
Gene Ther; 2007 Feb; 14(4):324-33. PubMed ID: 17051248
[TBL] [Abstract][Full Text] [Related]
12. Effect of the alterations in the fusion protein of measles virus isolated from brains of patients with subacute sclerosing panencephalitis on syncytium formation.
Ayata M; Shingai M; Ning X; Matsumoto M; Seya T; Otani S; Seto T; Ohgimoto S; Ogura H
Virus Res; 2007 Dec; 130(1-2):260-8. PubMed ID: 17825451
[TBL] [Abstract][Full Text] [Related]
13. Neutrophils contribute to the measles virus-induced antitumor effect: enhancement by granulocyte macrophage colony-stimulating factor expression.
Grote D; Cattaneo R; Fielding AK
Cancer Res; 2003 Oct; 63(19):6463-8. PubMed ID: 14559838
[TBL] [Abstract][Full Text] [Related]
14. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.
Yang S; Guo ZS; O'Malley ME; Yin X; Zeh HJ; Bartlett DL
Gene Ther; 2007 Apr; 14(8):638-47. PubMed ID: 17268533
[TBL] [Abstract][Full Text] [Related]
15. Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity.
Allen C; Vongpunsawad S; Nakamura T; James CD; Schroeder M; Cattaneo R; Giannini C; Krempski J; Peng KW; Goble JM; Uhm JH; Russell SJ; Galanis E
Cancer Res; 2006 Dec; 66(24):11840-50. PubMed ID: 17178881
[TBL] [Abstract][Full Text] [Related]
16. Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment.
Sugiyama T; Yoneda M; Kuraishi T; Hattori S; Inoue Y; Sato H; Kai C
Gene Ther; 2013 Mar; 20(3):338-47. PubMed ID: 22717740
[TBL] [Abstract][Full Text] [Related]
17. A matrix-less measles virus is infectious and elicits extensive cell fusion: consequences for propagation in the brain.
Cathomen T; Mrkic B; Spehner D; Drillien R; Naef R; Pavlovic J; Aguzzi A; Billeter MA; Cattaneo R
EMBO J; 1998 Jul; 17(14):3899-908. PubMed ID: 9670007
[TBL] [Abstract][Full Text] [Related]
18. Cell entry targeting restricts biodistribution of replication-competent retroviruses to tumour tissue.
Duerner LJ; Schwantes A; Schneider IC; Cichutek K; Buchholz CJ
Gene Ther; 2008 Nov; 15(22):1500-10. PubMed ID: 18509380
[TBL] [Abstract][Full Text] [Related]
19. Synergy between expression of fusogenic membrane proteins, chemotherapy and facultative virotherapy in colorectal cancer.
Hoffmann D; Bangen JM; Bayer W; Wildner O
Gene Ther; 2006 Nov; 13(21):1534-44. PubMed ID: 16791286
[TBL] [Abstract][Full Text] [Related]
20. Measles as a potential oncolytic virus.
Fielding AK
Rev Med Virol; 2005; 15(2):135-42. PubMed ID: 15546127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
